ArticleRenal failure2025
Impact of evolving strategies for arteriovenous graft creation and management on patency outcomes.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Biofunctionalized Vascular Access Graft Improves Patency and Endothelialization in a Porcine Arteriovenous Model.Journal of functional biomaterials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundArteriovenous grafts (AVGs) are essential alternatives for hemodialysis patients who are unsuitable for arteriovenous fistulas (AVFs). As surgical expertise and monitoring strategies evolve, understanding the long-term performance and influencing factors of AVGs is crucial.
methodsThis retrospective study analyzed 980 patients who underwent AVG creation at a single center between 2014 and 2022. Patients were grouped into three periods based on practice evolution. Primary and secondary patency rates at 6, 12, and 24 months were assessed via Kaplan-Meier's analysis, and Cox regression was used to identify independent predictors of secondary patency.
resultsNine hundred and eighty patients were included (period I: 110; period II: 379; period III: 491). Over time, significant changes were noted in graft type selection (standard to Intering), anastomosis site (from antecubital to basilic vein), and adoption of endovascular interventions. Secondary patency rates significantly improved from period I to III (log-rank
conclusionsOver nine years, procedural refinements and enhanced surveillance strategies have significantly improved AVG outcomes, particularly secondary patency. These findings support the growing role of AVGs as a reliable and sustainable vascular access option for hemodialysis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.